Development of Fast-dissolving Oral Dosage Form as Tablet using Binder as Vigna Mungo Mucilage and Oral Film using Solvent Casting Technique: Comparative Study

Main Article Content

Nilesh S. Kulkarni

Abstract

forms are the most preferred oral dosage forms as tablets and novel drug delivery as oral films. Sumatriptan
succinate is a new generation anti-migraine agent; Oral bioavailability of sumatriptan succinate is low due to
its severe first-pass metabolism. Materials and Methods: An attempt was made to develop fast-dissolving and
disintegrating oral tablet and oral film for the sumatriptansuccinate to avoid first-pass metabolism. To develop
a fast-dissolving tablet a natural mucilage powder extracted from vigna mungo. The tablet formulations were
prepared using 2, 4, and 6% mucilage solution as a binder. Similarly, the oral films containing polyvinyl alcohol:
soluplus or hydroxypropyl methyl cellulose: Soluplus were prepared by solvent casting method. The differential
scanning calorimetry and fourier transform infrared spectroscopy was carried out for plain drugs, blend of drugs
with mucilage, formed granules andoral film. The developed oral fast-dissolving tablet and oral fast-dissolving
film formulations were evaluated for drug content, In vitro dissolution study. Results and Discussion: Tablets
formulated with 2% mucilage (B1) binder require less disintegration time and 100% drug dissolution within
10 min. Film formulations containing HPMC K100M with soluplus containing 100 mg and 675 mg, respectively,
resulted disintegration within 25 seconds and 96% of drug dissolution within 5 min. Conclusion: Hence, the fastdissolving
dosage form was successfully developed as film formulation as compared to tablets for the sumatriptan
succinate.

Downloads

Download data is not yet available.

Article Details

How to Cite
Kulkarni, N. S. . (2023). Development of Fast-dissolving Oral Dosage Form as Tablet using Binder as Vigna Mungo Mucilage and Oral Film using Solvent Casting Technique: Comparative Study. Asian Journal of Pharmaceutics (AJP), 17(04). https://doi.org/10.22377/ajp.v17i04.5097
Section
ORIGINAL ARTICLES